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Abstract
Background: Four and a half LIM-only protein 2 (FHL2) has been implicated in multiple signaling pathways that regulate cell
growth and tissue homeostasis. We reported previously that FHL2 regulates cyclin D1 expression and that immortalized
FHL2-null mouse embryo fibroblasts (MEFs) display reduced levels of cyclin D1 and low proliferative activity.
Methodology/Principal Findings: Here we address the contribution of FHL2 in cell transformation by investigating the
effects of oncogenic Ras in FHL2-null context. We show that H-RasV12 provokes cell cycle arrest accompanied by
accumulation of p53 and p16
INK4a in immortalized FHL2
2/2 MEFs. These features contrast sharply with Ras transforming
activity in wild type cell lines. We further show that establishment of FHL2-null cell lines differs from conventional
immortalization scheme by retaining functional p19
ARF/p53 checkpoint that is required for cell cycle arrest imposed by Ras.
However, after serial passages of Ras-expressing FHL2
2/2 cells, dramatic increase in the levels of D-type cyclins and Rb
phosphorylation correlates with the onset of cell proliferation and transformation without disrupting the p19
ARF/p53
pathway. Interestingly, primary FHL2-null cells overexpressing cyclin D1 undergo a classical immortalization process leading
to loss of the p19
ARF/p53 checkpoint and susceptibility to Ras transformation.
Conclusions/Significance: Our findings uncover a novel aspect of cellular responses to mitogenic stimulation and illustrate
a critical role of FHL2 in the signalling network that implicates Ras, cyclin D1 and p53.
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Introduction
Four and a half LIM-only protein 2 (FHL2) is a multi-functional
protein that shuttles between focal adhesion sites and nucleus.
Focal adhesions are specialized adhesive junctions where integrin
receptors for extracellular matrix (ECM) are concentrated [1].
FHL2 interacts with a- and b-integrin subunits and focal adhesion
kinase (FAK) [2,3] and is involved in assembly of ECM proteins on
the cell surface [4]. Deregulation of genes involved in focal
adhesion, ECM-receptor interaction and response to external
stimuli has been evidenced in mouse embryo fibroblasts (MEF)
deficient for FHL2 [5], suggesting that FHL2 plays important roles
in tissue physiology and homeostasis and in the transduction of
signals emitted from extracellular environment. Indeed, in
response to RhoA signals or serum stimulation, FHL2 is
translocated to the nucleus [6,7] where it acts as either
transcription coactivator or corepressor in interaction with
numerous transcription factors including the androgen receptor,
AP1, CREB, PLZF, SKI, b-catenin, FOXO1, Runx2 and serum
response factor (SRF) [7,8,9,10,11,12,13,14,15,16]. The ability of
FHL2 to assemble multiple partners into protein complexes is
attributed to its LIM-domain structure that serves as protein
binding interface through double zinc finger motifs [17]. Thus,
FHL2 participates in regulating expression of a large spectrum of
genes involved in cell proliferation, differentiation, transformation
and apoptosis. Despite absence of gross defects during develop-
ment, FHL2-deficient mice harbor cardiac hypertrophy in
response to b-adrenergic stimulation, osteopenia due to decreased
activity of osteoblasts and wound healing defect [15,18,19].
Several lines of evidence have implicated FHL2 in the control of
cell proliferation. We have recently shown that FHL2 physically
occupies the cyclin D1 promoter and directly stimulates cyclin D1
transcription [5]. Accordingly, we found reduced expression levels of
cyclin D1 in MEFs isolated from FHL2-null mice. After spontaneous
immortalization, these cells exhibited weak proliferative capacity
associated with low expression levels of all D-type cyclins and cyclin
E, as well as cyclin-dependent kinase (Cdk) inhibitors, in particular
p16
INK4a [5,20]. It has been shown that FHL2 can inhibit the
antiproliferative functions of the transcription factor E4F1 by
inhibiting the transcription repressor function and p53 binding
activity of E4F1 [21]. In gastric and colon cancer cell lines,
suppression of FHL2 inhibited anchorage-dependent and -indepen-
dent cell growth, and tumor formation in nude mice xenograft [22].
In line with its effects on cell growth, overexpression of FHL2 has
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androgen-induced nuclear accumulation of FHL2 in highly
malignant prostate carcinoma has been linked to disease progression
and poor outcome [6,25].
In this study, we sought to gain further insight into the role of
FHL2 in neoplastic transformation by investigating the effects of
oncogenic Ras in a FHL2-deficient context. In primary rodent
cells, activated Ras mutant induces premature senescence
associated with activation of p16
INK4a and p53 [26]. Cellular
senescence involves an essentially irreversible cell cycle arrest that
is associated with heterochromatin formation mediated by the
retinoblastoma (Rb) tumor suppressor [27]. The ARF/p53 and
p16
INK4a/Rb pathways are clearly critical for establishing the
senescence growth arrest, and primary MEFs deficient for p19
ARF
and p53 exhibit resistance to Ras-induced senescence and are
susceptible to transformation by activated Ras alone [28]. In
general, cooperation of Ras and additional ‘‘immortalizing’’
factors is required for transformation of primary rodent cells.
However, oncogenic Ras alone readily transforms immortalized
cells lines, since 80% of these cells contain mutant p53, whereas
most others sustain biallelic loss of the INK4a/ARF locus [29].
Here, we report that H-RasV12 provokes a cell cycle arrest in
spontaneously immortalized FHL2-null cells, in contrast to cell
transformation in wild type (wt) counterparts. The cell growth arrest
induced by Ras is controlled by p53 which remains wt after
spontaneous immortalization of FHL2-null cells. We found that under
continuous Ras-mediated mitogenic stimulation, D-type cyclins are
dramatically increased in FHL2-deficient cells, resulting in reversal of
the growth arrest without disrupting the ARF/p53 checkpoint.
Results
Absence of foci formation in immortalized FHL2
2/2
fibroblasts upon H-RasV12 expression
We have recently reported the establishment of spontaneously
immortalized cell lines from primary MEFs derived from FHL2
2/
2 embryos [30] by using a 3T3 protocol [5]. To assess the effects
of FHL2 deficiency on cell transformation, we expressed the
oncogenic form H-RasV12 in three independent immortalized wt
and FHL2
2/2 MEF cell lines. Transiently transfected cells were
analyzed for the loss of contact inhibition by focus formation
assays. As expected, numerous colonies were detected in wt
fibroblasts, but strikingly, no colonies developped in immortalized
FHL2
2/2 MEFs (Figs. 1A and 1B), despite similar levels of Ras
expression in these cell lines as shown by immunoblotting (Fig. 1C).
To confirm that FHL2 deficiency was directly involved in this
phenotype, we then re-expressed FHL2 from a retroviral vector in
primary FHL2
2/2 MEFs at early passage. Continuous passage of
FHL2-restored MEFs readily gave rise to established 3T3 cell lines
in which the levels of FHL2 protein were significantly lower than
in wt MEFs (Fig. 1B). Transfection of the Ras vector in FHL2-
restored MEF lines resulted in colony formation, although
transformation efficiency was about half of that in wt MEFs
(Figs. 1A and 1B). Thus, low level FHL2 expression was sufficient
to restore the capacity of immortalized MEFs to undergo
deregulated growth and loss of contact inhibition in response to
oncogenic Ras. These results indicate that FHL2 deficiency
impairs Ras-induced transformation of immortalized MEFs.
H-RasV12 induces a cell cycle arrest in immortalized
FHL2
2/2 MEFs
It has been shown that oncogenic Ras can induce either
transformation, senescence or apoptosis, depending on the cell
context [31]. To further investigate the effects of Ras in the
context of FHL2 deficiency, immortalized wt, FHL2
2/2 and
FHL2-restored cells were infected with pBabe-RasV12 or control
pBabe retrovirus and selected for drug resistance. Both Ras-
transduced wt and FHL2-restored MEFs exhibited thin, elongated,
and spindle-like morphology and loss of contact inhibition
characteristic of transformed fibroblasts (Fig. 2A). Moreover,
when injected s.c. into BALB/c nude mice, Ras-transduced wt and
FHL2-restored fibroblasts generated large tumors in 6/6 mice. In
control experiment, none of the 6 mice injected with vector-
transduced wt or FHL2-restored cells developed tumors.
In sharp contrast, H-RasV12 transduction produced very
different morphological changes in immortalized FHL2
2/2 cell
lines. Cells in these cultures were large, flat and nonrefractile
(Fig. 2A), evoking a senescent-like morphology that could not be
detected in transient assays, in which non-transfected cells were
predominant (see Fig. 1A). Three independent FHL2
2/2 lines
displayed similar morphology upon Ras expression (data not
shown). However, b-galactosidase activity [32] could not be tested
as a senescence-associated marker in this system, because the lacZ
cDNA was inserted at the FHL2 locus for generating FHL2-null
mice [30], resulting in b-galactosidase activity in all FHL2
2/2 cells
even at acidic conditions (Fig. 2B).
To better characterize the phenotype of H-RasV12-transduced
immortalized FHL2
2/2 cells, we first examined whether these cells
were growth arrested by monitoring their proliferative activity,
using immunostaining with a Ki-67 specific antibody. While
positive signals were observed in FHL2
2/2 cells transduced with
the pBabe vector, no Ki-67-positive cell was detected in H-
RasV12-transduced FHL2
2/2 cultures (Fig. 2C). We then assessed
the expression of genes that are specifically associated with the G1
arrest induced by oncogenic Ras in fibroblasts, namely p53 and
the cyclin–dependent kinase (Cdk) inhibitors p21
CIP1 and
p16
INK4a that promote cell cycle arrest via the Rb tumor
suppressor pathway. Immunoblotting analysis revealed that
expression of oncogenic Ras was associated with increased levels
of p53, p21
CIP1 and p16
INK4a in FHL2
2/2 MEFs, but not in wt
cells (Fig. 2D). The basal level of p16
INK4a was extremely low in
FHL2
2/2 cells [5] (Fig. 2D). It has been demonstrated that high
levels of p16
INK4a provide a dominant second barrier to the
unlimited growth of human fibroblasts [33]. The induction of
p16
INK4a by Ras in FHL2
2/2 cells may provide an alternative
mechanism of p53 activation for cell cycle exit. In addition,
consistent with previous reports showing that cyclin D1 is activated
by oncogenic Ras in both senescent and transformed fibroblasts
[26,34], we found equally high level expression of cyclin D1 in wt
and FHL2
2/2 cells (Fig. 2D). The fold increase of cyclin D1 by
Ras was more dramatic in FHL2
2/2 cells, given its low basal level
(Fig. 2D) [5].
Based on the observed morphological and biochemical changes,
it seems likely that Ras-induced cell cycle arrest of immortalized
FHL2
2/2 cells was triggered by a senescent-like program that
involves p53 and p16
INK4a. This cell cycle arrest corresponds to
the model of hypermitogenic arrest that is associated with a ‘large
cell’ morphology and protein synthesis [35].
Immortalized FHL2
2/2 MEFs retain wt p53 and an intact
INK4a/ARF locus
Previous studies have shown that 80% of spontaneously
immortalized MEF cell lines harbor mutant p53 alleles, whereas
most of the others sustain biallelic loss of the INK4a/ARF locus
[29]. However, the low basal level of p53 and its activation by H-
RasV12 in immortalized FHL2
2/2 MEFs suggest that these cells
may harbor wt p53 (Fig. 2D). We assessed the p53 status of
immortalized MEFs by treating cells with doxorubicin (doxo), a
FHL2 in Cell Transformation
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p53, but has no effect on the already stabilized p53 mutants.
Detection of p53 was optimized by immunoprecipitating the
protein from cell lysates before immunoblotting. In established wt
cell lines, basal p53 levels were high in the absence of any stimulus,
and did not increase in response to doxo (Fig. 3A), reflecting the
hallmarks of p53 mutants. In sharp contrast, p53 was produced at
low levels and was significantly induced by doxo in all five FHL2
2/
2 cell lines (Fig. 3A), consistent with the presence of wt p53. We
therefore went on to analyze the p53 gene by direct PCR
sequencing of genomic DNA in four independent FHL2
2/2 cell
lines. Using a set of five PCR fragments covering exons 4 to 10,
both strands of each exon were sequenced. Of four FHL2
2/2 cell
lines analyzed, we did not detect any mutation, which confirms the
wt status of p53 in immortalized FHL2
2/2 cells.
Analyses of p19
ARF expression in immortalized FHL2-null cell
lines reproducibly showed the presence of the protein in all cell
lines, regardless of FHL2 genotype (Fig. 3B). However, the p19
ARF
protein was generally present in larger amounts in wt than in
FHL2
2/2 cell lines, in agreement with previous reports showing
that p19
ARF is up-regulated in cells with mutant p53 [36]. As
reported previously, low levels of p16
INK4a were detected in all
clones [5]. Based on these observations, we conclude that the
INK4a/ARF locus remained intact in these cells. Disruption of
p19
ARF or p53 is therefore not required for immortalization of
FHL2
2/2 MEFs.
Microarray analysis shows up-regulation of p53 target
genes in FHL2-deficient cells
To confirm that the p53 pathway remained functional in
FHL2
2/2 cell lines, we assessed the expression of p53 target genes
at the whole-genome level by comparing gene expression profiles
of three FHL2
2/2 cell lines with those of three immortalized wt
MEF clones using Affymetrix Mouse Genome 430 2.0 micro-
array[5]. Up-regulation of p53 target genes in FHL2
2/2 cells was
evidenced by Gene Set Enrichment Analysis (GSEA), a compu-
tational method for assessing enrichment of a predefined gene list
in one class compared with another [37]. Using a list of thirty one
p53 target genes of the Molecular Signatures Database (MSigDB)
[38] as gene set, we found that 61% of these genes were
significantly up-regulated in FHL2
2/2 cells (Fig. 4A). Specifically,
several well-studied p53 target genes such as p21
CIP1, Fas and
cyclin G1 were increased in cells lacking FHL2. As the Cdk
inhibitor p21
CIP1 is a downstream effector of p53, we then
Figure 1. Absence of foci formation in immortalized FHL2
2/2 MEFs upon expression of H-RasV12. (A) Focus formation assay of MEFs
transiently transfected with H-RasV12 or empty vector. Plates were stained with Giemsa at 3 weeks after transfection. Data are representative of at
least 3 independent experiments using 3 spontaneously immortalized clones. To restore FHL2 expression, primary FHL2
2/2 MEFs were infected with a
retrovirus expressing FHL2 (pBabeFHL2puro) and cultured according to the 3T3 protocol. Two FHL2-restored FHL2
2/2 cell pools were obtained and
used in the study. pBabe vector was used as a control (Babe). (B) Chart depicting at least three independent experiments. Mean colony
numbers6standard deviation are shown. Bottom: Immunoblot analysis of FHL2 expression in FHL2-restored cell line. (C) Analysis of H-RasV12
expression in MEFs transfected with either empty (V) or H-RasV12 (R) expression vector. Samples were processed for immunoblotting 48 h after
transfection. Actin was used as loading control.
doi:10.1371/journal.pone.0003761.g001
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CIP1 in
FHL2
2/2 cells. For GSEA, we used a set of 39 genes that were
down-regulated after ectopic expression of p21
CIP1 in ovarian
cancer cell lines [39], and found decreased expression in 61% of
these genes in FHL2
2/2 MEFs (Fig. 4B). It included genes
encoding aurora kinases, Mcm proteins, Kntc1, Cep55 and
Cdc25b that are implicated in DNA replication, activation of M-
phase, kinetochore assembly and chromosome segregation.
Downregulation of these genes is consistent with the known effects
of p21
CIP1 on G1 and G2/M phase arrest [40]. Real-time RT-
PCR analysis confirmed altered expression of p53 targets such as
p21
CIP1 and Pltp, and down-regulation of p21
CIP1 downstream
genes such as Ube2c, Ccdc99 and Tubb3 in FHL2
2/2 cells
(Fig. 4C). Taken together, genome-wide analysis firmed up the
functional activity of p53 and provided insight into the impact of
functional p53 on gene expression in immortalized FHL2-null
cells.
Inactivation of p53 confers susceptibility to Ras-induced
transformation in FHL2
2/2 cells
Integrity of the p19
ARF/p53 pathway is required for induction
of cellular senescence by oncogenic Ras [41]. To determine
whether p53 inactivation could alter the effects of H-RasV12
expression in FHL2
2/2 MEFs, we first used the E6 oncoprotein of
human papillomavirus-16 that causes p53 degradation and
abolishes p53-mediated checkpoints. Retroviral transduction of
E6 before transient transfection of immortalized FHL2
2/2 cell
lines with H-rasV12 resulted in efficient colony formation (see
Fig. 3C), thus allowing efficient transformation of these cells.
Moreover, co-expression of a dominant negative form of p53,
p53DD [42] and H-RasV12 by retroviral vectors in FHL2
2/2
cells resulted in thin, elongated, and spindle-like transformed
morphology (see Fig. 3D). When injected s.c. into BALB/c nude
mice, Ras- and p53DD-cotransduced FHL2-null fibroblasts
induced tumor formation in 4/4 mice, whereas no tumor
developped in 4 mice injected with FHL2
2/2 cells transduced
with p53DD alone. Thus, p53 inactivation was sufficient to restore
the susceptibility of immortalized FHL2
2/2 MEFs to Ras-
mediated transformation.
The cell cycle arrest induced by H-RasV12 in
immortalized FHL2
2/2 MEFs is reversible
The morphology of Ras-transduced FHL2
2/2 cells evoked
cellular senescence that involves an essentially irreversible cell
cycle arrest. When cultured with the 3T3 protocol, however, Ras-
transduced FHL2
2/2 cells resumed proliferation after 5 passages.
At passage 10, thin and spindle-like morphology characteristic of
transformed fibroblasts appeared, in sharp contrast to the initial
large cell size and flat ‘‘senescent’’ morphology (Fig. 5A, compare
passage 10 to passage 0). Similar data were obtained in 3
independent Ras-expressing FHL2
2/2 cell lines (data not shown).
When injected into nude mice, Ras-transduced FHL2
2/2 cells at
passage 10 gave rise to tumors in 3/3 animals.
Figure 2. H-RasV12 induces cell cycle arrest in immortalized FHL2
2/2 MEFs. (A) Immortalized wt, FHL2
2/2 and FHL2
2/2-restored MEFs were
infected with pBabe-RasV12 or control pBabe retrovirus and selected for drug resistance. (B) All FHL2
2/2 cells were positive in b-galactosidase assay
due to the insertion of Lac Z cDNA at the FHL2 locus. (C) Ki-67 immunofluorescence analysis in vector- and H-RasV12-transduced FHL2
2/2 MEFs.
Nuclei were counterstained with DAPI. (D) Expression of Ras, p53, p21
CIP1, p16
INK4a and cyclin D1 in H-RasV12- (R) or vector- (V) transduced wt and
FHL2
2/2 cell lines. Equal amounts of protein extracts were analyzed by immunoblotting.
doi:10.1371/journal.pone.0003761.g002
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2/2 cells contrasts with
the permanent cell cycle arrest induced by Ras in primary rodent
cells. To determine the role of p53 in the escape of Ras-transduced
FHL2
2/2 cells from growth arrest, we measured the protein levels
of p53 in FHL2
2/2-transformed cells. After treatment with doxo,
cell lysates were analyzed for p53 expression by immunoblotting.
The basal levels of p53 in Ras-transduced FHL2
2/2 cells were
higher than those in vector-transduced FHL2
2/2 cells, consistent
with the induction of p53 in these cells by Ras (see Fig. 2D).
However, p53 was still significantly induced by doxo in Ras-
transduced FHL2
2/2 cells after reversal of the growth arrest, as
well as in vector-transduced FHL2
2/2 control cell lines (Fig. 5B).
These data suggested that p53 remained wt, which was further
confirmed by sequencing p53 exons 4 to 10 in three different Ras-
transduced FHL2
2/2 cell lines (data not shown). In contrast, no
p53 induction by doxo was detected in Ras-transduced wt cells, as
expected for the p53 mutant status (Fig. 5B). We then assessed the
INK4a/ARF locus by examining expression of p16
INK4a and
p19
ARF by immunoblotting. High levels of p16
INK4a were
maintained in these cells after reversal, whereas a moderate
increase of p19
ARF expression was detected in the same cell
population (Fig. 5C). These data indicate that the reversal of Ras-
imposed cell cycle arrest in FHL2
2/2 cells was not associated with
disruption of the p19
ARF/p53 pathway.
We have previously reported that FHL2 deficiency in immortal-
ized MEFs is associated with low levels of cyclins D1, D2, D3 and E,
and with hypophosphorylation of Rb [5]. The ability of Ras to
activate cyclin D1 in both senescent and immortal cells [26,34]
prompted us to examine the expression of cyclin D1 and several
other cell cycle regulators in Ras-tranduced FHL2
2/2 cells after
reversal. We found that oncogenic Ras induced up-regulation of
cyclinD1,but not D2and D3 inwtcells (Fig. 5C), inagreement with
previous report [43]. Strikingly, drastic induction was observed not
only for cyclin D1, but also for cyclins D2, D3 and E in Ras-
expressing FHL2
2/2 cells (Fig. 5C). In consequence, Rb phosphor-
ylation was significantly augmented in these cells (Fig. 5C).
Expression of H-RasV12 considerably potentiated the growth of
FHL2
2/2 cells, although the proliferative rate remained slightly
lower than that of Ras-transduced wt cells (Fig. 5D). Thus, in
immortalized FHL2
2/2 cells, Ras-induced cell cycle arrest appeared
to be a transient phenotype, and escape of the cell cycle arrest might
be triggered by activation of G1-S cyclins by prolonged Ras
expression, in turn leading to Rb phosphorylation. These observa-
tions indicate that if integrity of the p19
ARF/p53 pathway is crucial
for establishing cell cycle arrest in FHL2
2/2 cell lines upon Ras
expression, inactivation of Rb by increased cyclin/Cdk activity may
be sufficient to reset their replicative lifespan. The resumed
proliferative capacity diverts Ras activity to cell transformation.
Figure 3. Analysis of the p53/ARF pathway in immortalized FHL2
2/2 MEFs. (A) Functional analysis of the p53 protein. After induction by
doxorubicin (doxo), p53 was immunoprecipitated from immortalized MEFs and analyzed by immunoblotting. Wild type clones are indicated by
capital letters and FHL2
2/2 clones by lower-case letters. p53 induction was determined as the ratio of the relative p53/actin intensities after doxo
treatment to p53/actin intensities without doxo in each cell line. (B) Western blot analysis of p19
ARF expression in seven immortalized clones of each
FHL2 genotype. (C) Human papillomavirus E6 oncoprotein restores Ras-mediated transformation in immortalized FHL2
2/2 MEFs. Cells were infected
with E6-expressing retrovirus (HPVE6) or control virus (Babe), and then transiently transfected with H-RasV12 plasmid or control vector, cultured for 3
weeks without splitting and stained. Data are representative of three independent experiments in two independent E6-transduced FHL2
2/2 MEF
clones. (D) Dominant negative p53 (p53DD) was expressed alone or coexpressed with H-RasV12 by retroviral vectors in immortalized FHL2
2/2 MEFs.
doi:10.1371/journal.pone.0003761.g003
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PLoS ONE | www.plosone.org 5 November 2008 | Volume 3 | Issue 11 | e3761Figure 4. Expression of p53 and p21
CIP1 target genes in FHL2-null cells (A) Left: GSEA plot using a gene set of up-regulated p53-dependent genes
from the Molecular Signatures Database (MSigDB) (NES=2.35, FDR,0.01, p,0.0001). Enrichment score (ES) reflects the correlation of the gene set
with FHL2
2/2 (KO) and WT genotypes. Middle: Core group of genes of the up-regulated p53-dependent gene set that contributed to the ES. The fold
change (KO/WT) value for genes that have more than one probe set corresponds to the mean value. Right: Expression profile of the deregulated
genes at fold change $1.4 in 3 different clones for each genotype. Data are plotted as a heatmap where red and blue correspond to high and low
expression in log2-transformed scale. (B) GSEA Analysis using down-regulated p21
CIP1-dependent gene set of MSigDB (NES=22.25, FDR,0.01,
p,0.0001). Expression profile of the top down-regulated genes at fold change #0.8 that are differently expressed in the FHL2
2/2 compared to wt
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of FHL2
2/2 cells to transformation by oncogenic Ras
To directly evaluate the role of cyclin D1 in transformation of
FHL2-null cells, we used immortalized cyclin D1-HA/FHL2
2/2
MEFs derived from primary FHL2
2/2 cells transduced with a
retroviral vector for HA-tagged cyclin D1 (Fig. 6A) [5]. We have
previously shown that expression of cyclins D1, D2, D3 and E
and Rb phosphorylation as well a cell proliferation were restored
to normal levels in these cells [5]. The effects of cyclin D1
restoration on the cellular response to mitogenic stimulation
were evaluated after retroviral-mediated transfer of H-RasV12
in immortalized wt, FHL2
2/2, pBabe-infected FHL2
2/2and
cyclin D1-HA/FHL2
2/2 cells. The Ras-transduced cyclin D1-HA/
FHL2
2/2 cells showed a thin, elongated and spindle-like
morphology similar to wt MEFs transformed by Ras (Fig. 6B),
in contrast with the senescent morphology of Ras-transduced
pBabe-infected FHL2
2/2 cells (see Fig. 2A and data not shown).
When assayed for their ability to grow in soft agar, Ras-
transduced cyclin D1-HA/FHL2
2/2 cells formed colonies at
similar efficiency as wt MEFs (0.04%), whereas no colony was
detected in cyclin D1-HA/FHL2
2/2 cells infected with the empty
vector (Fig. 6C).
The observed susceptibity of cyclin D1-HA/FHL2
2/2 cell lines
to Ras-induced transformation led us to examine the p53 status
of these cells by comparing p53 expression levels in basal
conditions and after doxo treatment. The p53 levels in cyclin D1-
HA/FHL2
2/2 cells were as high as those in wt MEFs in the
absence of treatment, and did not increase in response to doxo,
reflecting mutant p53 (Fig. 6D), and similar results were
obtained with two independent cyclin D1-HA/FHL2
2/2 cell
Figure 5. Reversal of the cell cycle arrest in H-RasV12-transduced FHL2
2/2 MEFs. (A) The indicated cell lines transduced by H-RasV12 or
control vector are shown at cell cycle arrest stage (passage 0) and after reversal of the cell cycle arrest (passage 10). (B) Analysis of the p53 protein in
cells at passage 10 after H-RasV12 transduction. Cells were treated with doxorubicine as described in Fig. 3A. (C) Western blot analysis of cell cycle
regulators in wt and FHL2
2/2 cell lines at passage 10 after transduction with H-RasV12 (R) or empty vector (V). (D) Growth curves of the indicated cell
lines after reversal. Equal numbers of cells were initially plated in triplicate wells, and cells were counted at indicated times. Mean values6standard
deviation from three independent experiments are shown. Data presented are representative of 3 independent H-RasV12- and vector-expressing MEF
lines.
doi:10.1371/journal.pone.0003761.g005
clones. Abbreviations: NES: normalized enrichment score, FDR: false discovery rate. (C) Quantitative RT-PCR analysis of Cdkn1a (p21
CIP1), Pltp, Ube2c,
Ccdc99, Tubb3 transcripts in three independent wt and FHL2
2/2 immortalized clones. Data were normalized to 18S RNA. Results are expressed as
relative expression of each gene/18S RNA assuming wt cells as 1.0. Average values and standard deviations for three independent experiments are
shown.
doi:10.1371/journal.pone.0003761.g004
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FHL2
2/2 MEFs showed typical features of wt p53, with low
basal levels of p53 and positive response to doxo stimulation.
These findings suggest that restoration of cyclin D1 re-routed
FHL2
2/2 cells to the common immortalization pathway
associated with loss of p53 function and sensitivity to Ras
transformation.
Discussion
This study, showing that oncogenic Ras provokes a proliferative
arrest in immortalized FHL2
2/2 MEFs, uncovers a yet undoc-
umented effect of Ras in the context of immortal mouse cell lines.
We found that loss of FHL2 signalling confers immortalized MEFs
the ability to retain an intact ARF/p53 checkpoint that is essential
for Ras induction of cell cycle arrest, at difference with wt cell lines
in which the ARF/p53 pathway is disrupted by mutation of p53 or
deletion of the INK4a locus [29]. We provide evidence that the
cyclin D/Rb pathway is critical in the regulation of cell cycle and
transformation in FHL2-deficient cells.
Low levels of cyclin D may override the requirement for
disruption of the ARF/p53 checkpoint during
establishment of FHL2
2/2 cell lines
By genetic, biochemical and gene expression profile analyses,
we show that immortalized FHL2
2/2 MEFs retain wt ARF and
p53, implying alternative mechanisms for immortalization of
FHL2-deficient cells. Although primary FHL2
2/2 MEFs undergo
replicative senescence followed by emergence of immortalized
variants with similar kinetics as in wt cells, immortalized FHL2
2/2
Figure 6. Immortalized FHL2
2/2 MEFs stably expressing cyclin D1 are susceptible to transformation by oncogenic Ras. (A) Increased
cyclin D1 expression in immortalized FHL2
2/2 MEFs after introduction of cyclin D1-HA transgene was confirmed by immunoblotting with anti-cyclin
D1 and anti-HA antibodies. (B) Representative phase contrast images of immortalized wt and cyclin D1-HA/FHL2
2/2 cell lines transduced with H-
RasV12 or empty vector. (C) Soft agar assay. Cells were initially seeded at 5610
4 cells/plate and cultured for 10 days. Images are representative of
three wt and two cyclin D1-HA/FHL2
2/2 cell lines transduced with H-RasV12. (D) Western blot analysis of p53 induction by doxorubicin in the
indicated cell lines as described in Fig. 3A.
doi:10.1371/journal.pone.0003761.g006
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reduced growth rate associated with down-regulation of cyclins
D1, D2 and D3 (Fig. 5C and [5]). Spontaneous senescence occurs
in the presence of mitogens [35]. Because D-type cyclins are
critical cell cycle sensors of mitogens, decrease of all D-type cyclins
may be sufficient for primary cells to bypass the growth arrest
induced by the tissue culture environment. Such process might be
selected in FHL2-deficient cells, with emergence of variants with
low expression of cyclin D that may not fully sense hypermitogenic
signals in the culture environment. By enabling cells to escape
mitogen-induced senescence, this process might circumvent the
need for loss of p53 or ARF. Thus in the absence of FHL2
signalling, we propose that decreasing sensitivity to mitogenic
signals may, in part, account for an alternative mechanism of cell
immortalization. This notion is supported by our observation that
upon restoration of cyclin D1 expression in FHL2
2/2 cells,
disabling the p53/ARF checkpoint becomes central to the
establishment of cyclin D1-HA/FHL2
2/2 MEF lines as for wt
cells. It suggests that the interplay between expression of mitogenic
sensors and p53 functions might control cell growth or arrest in
response to various stresses imposed by tissue culture. This
hypothesis is consistent with previous observations showing that
primary cyclin D1, D2 and D3 triple knock-out MEFs display
reduced susceptibility to oncogenic agents [44].
The integrity of the ARF/p53 pathway is responsible for
Ras-induced cell cycle arrest in immortal FHL2
2/2 cell
lines
Immortalization is thought to endow cells with sensitivity to
oncogene-induced transformation. Instead, the response of
immortalized FHL2
2/2 MEFs to oncogenic Ras was character-
ized by cell cycle arrest associated with a senescent-like
morphology and significant increase in p53, p21
CIP1 and
p16
INK4a. Similar findings have been reported in normal human
fibroblasts in which ectopic telomerase expression was sufficient
for immortalization, but the introduction of Ras induced
senescence [45]. In murine systems, it has been shown that cell
immortality alone is not sufficient for transformation of KSR1
2/2
cells by Ras, and that disruption of the MAP kinase scaffold
protein KSR1 directly blocks transduction of the Ras signal [46].
In FHL2
2/2 MEFs, resistance to Ras-mediated transformation
might rather reflect the integrity of the ARF/p53 checkpoint,
which senses inappropriate mitogenic signals and diverts cells to
p53-dependent cell cycle arrest. This notion is supported by our
finding that impairment of p53 function by overexpression of E6
or p53DD restores the susceptibility of FHL2
2/2 cells to Ras-
induced transformation.
Activation of cyclin D by Ras can override the p53-
dependent growth arrest of FHL2
2/2 cells
D-type cyclins represent the ultimate recipients of Ras
oncogenic signal, and Ras can drive cell proliferation through all
three D-cyclins [43]. Curiously, Ras activated all three D-cyclins
in FHL2
2/2 cells, but failed to upregulate cyclins D2 and D3 in wt
fibroblasts (this study and [43]), suggesting that FHL2 signalling
has impact on all three D-cyclins. In turn, the dramatic increase in
cyclin D led to efficient phosphorylation of Rb in FHL2
2/2 cells.
The Rb tumor suppressor is required for senescence-associated
heterochromatic foci (SAHF) formation and E2F target gene
silencing, thus essential for the stability of senescent state in human
fibroblasts [27]. However, SAHF formation in MEFs is less
pronounced than in human fibroblasts [27] and senescent MEFs
can rapidly re-enter cell cycle upon disruption of the p53 pathway
[47]. These observations suggest that the control of the stability of
senescence in mouse fibroblasts may be less dependent on Rb than
in human fibroblasts and that p53 is required for both induction
and maintenance of senescence in murine cells. It has been
proposed that either inactivating p16
INK4a, p21
CIP1, p53 and Rb
or re-activating cell cycle by c-myc, E2F, CDK2 and viral
oncoproteins are required for overcoming senescence [48]. In the
absence of p53 defects, the mechanisms involved in reversal of the
cell cycle arrest in FHL2-deficient cells remain to be elucidated. A
possible interpretation of our data might be that induction of G1-S
cyclins by Ras eventually counteracts the p53-dependent prolifer-
ative block, leading to re-entry into the cell cycle and cell
transformation.
FHL2 provides a unique mechanism in transcellular coordina-
tion and signal transduction by shuttling between focal adhesions
and the nucleus. The up-regulation of FHL2 observed in human
cancers suggests a potential role of FHL2 in the oncogenic process.
This study demonstrates that the absence of FHL2 signalling
provides a brake to cell transformation in tissue culture system.
Suppression of FHL2 by antisense and siRNA methods has been
shown to inhibit growth of gastric and colon cancer cell lines [22].
In mouse model, loss of FHL2 markedly decreases intestinal polyp
formation induced by activation of the Wnt/b-catenin pathway
(C.L., Y.N., F.L., S. Colnot, J. Chen, C. Perret, M.A.B. and Y.W.,
unpublished data). These results indicate that FHL2 signalling is
important in the process of cell transformation and that its
deficiency is benefitial for inhibition of this process. Treatment
targeting FHL2 may thus provide a viable and specific strategy for
cancer therapy.
Materials and Methods
Cell culture
Wild type and FHL2
2/2 MEFs have been described previously
[5]. Cells were cultured in Dulbecco’s modified Eagle’s medium
(DMEM) with 10% fetal bovine serum. Cell proliferation was
determined by plating 2.5610
4 cells into 12-well plates in
triplicate. Following initial plating, cells were harvested and
counted for 6 days.
Retroviral vectors and gene transfer
pWZLH-RasV12hygro was kindly provided by Dr. Scott Lowe.
The pBabe-E6neo and pBabeH-RasV12puro retroviral vectors
were gifts from Dr. Oliver Bischof. The pBabe-hygro p53DD
construct from Dr. Bob Weinberg’s lab [42] and the pBabe-puro-
cyclinD1-HA from Dr. William Hahn’s lab were obtained from
Addgene (Addgene plasmids 9058 and 9050 respectively). The
pBabe-FHL2puro was described previously [5]. Phoenix ecotropic
virus packaging cells in 10 cm-culture dishes were transfected by
phosphate calcium precipitation with 10 mg of retroviral vector.
After 48 h, the virus-containing medium was filtered and
supplemented with 8 mg/ml polybrene. For infection, the culture
medium of target fibroblasts was replaced by virus-containing
medium and incubated at 37uC for 3 h. The infection process was
repeated three times, followed by drug selection.
Transformation assays and tumorigenesis
For focus assays, cells were plated at 5610
5 cells in 10-cm
culture dish. Cells were either transfected with 10 mg of either
pCMV-H-RasV12 [49] or empty vector by using lipofectamine
(Invitrogen), or infected with pBabe-E6neo and pBabe without
selection. Cells were fed twice weekly and stained with Giemsa 3
weeks later. To generate stable cell lines expressing Ras and
p53DD, MEFs were infected with virus-containing supernatant
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retroviral vectors pWZLH-RasV12Hygro, pBabeH-RasV12puro,
and pBabe-hygro p53DD, followed by drug selection. For soft agar
assays, cells were resuspended in 0.3% agarose in DMEM
supplemented with 10% FBS at a density of 5610
4 cells per well
in six-well plates and plated in triplicate onto solidified 0.6%
agarose-containing medium. Colonies were counted and photo-
graphed 10 dyas after plating. For in vivo tumorigenesis assays, 5 to
10610
6 cells were implanted s.c. into the flanks of 8 week old
female athymic BALB/c mice (Charles River Laboratories).
Tumor growth was monitored for 2 to 3 weeks, and mice were
sacrificed when the maximal allowable tumor size was achieved.
No tumor developped during an observation period of 10 weeks in
control groups. All animal procedures were carried out in
accordance with French government regulations. Mice were
housed under pathogen-free conditions.
Immunoblotting
Cellular extracts were prepared in lysis buffer (50 mM Tris-HCl
pH 7.5, 250 mM NaCl; 0.5% NP-40; 250 mM EDTA; 1 mM
DTT; protease inhibitor cocktail (Roche)). Proteins were analyzed
by immunoblotting as described previously [20]. The following
primary antibodies were used: anti-H-Ras (sc-29), anti-p53 (sc-
6243), anti-p21
CIP1 (sc-397), anti-p16
INK4a (sc1207), anti-cyclin D1
(sc-450), cyclin D2 (sc-181) and cyclin D3 (sc-182) from Santa
Cruz, anti-p19
ARF (ab80) from Abcam, anti-Rb (554136) from BD
Pharmingen, anti-FHL2 (K0055-3) from MBL, anti-HA (Babco)
and anti-actin (Sigma).
p53 induction and immunoprecipitation
MEFs (1610
6 cells per well) were treated with 1 mg/ml
doxorubicin and lysed 24 h later in IP buffer (50 mM Tris-HCl
pH 7.5, 300 mM NaCl; 0.5% Triton 6100; 1 mM DTT;
protease inhibitor cocktail (Roche)). The lysate was cleared by
centrifugation and incubated with a mixture of monoclonal
antibodies against p53 (0.5 mg; Pab 246 and Pab240, Santa
Cruz) in the presence of protein A/G-Sepharose beads (Pierce).
Proteins were analyzed by immunoblotting with anti-p53
antibody. Signals were quantified using Gene Snap/Gene Tools
from SynGene.
Direct PCR sequencing
DNA fragments spanning p53 exons 4–10 were amplified from
0.1–0.2 mg of genomic DNA with the following primers: for exons
4–5, 59-TGGTGCTTGGACAATGTGTT-39 (forward) and 59-
AGACGCACAAACCAAAACAA-39 (reverse); for exon 6, 59-
GTAGGGAGCGACTTCACCTG-39 (forward) and 59-CA-
GAAGCTGGGGAAGAAACA-39 (reverse); for exons 7–8, 59-
CCTTGTGCTGGTCCTTTTCT-39 (forward) and 59-ATGC-
GAGAGACAGAGGCAAT-39 (reverse); for exon 9, 59-
TGTCCAGTGCTTCCATCTCA-39 (forward) and 59-GGAGG-
GAGGTCTGGGTAGAG-39 (reverse); for exon 10, 59-
GGTGATGATGGTGATGGTGA-39 (forward) and 59-
TATGGCGGGAAGTAGACTGG-39 (reverse). For all exons,
sequencing primers consisted of common sequences, are attached
to the 59 end of forward primers (59-GTAAAACGACGGC-
CAGT-39), and to the 59 of the reverse primers (59-CACACAG-
GAAACAGCTATGACCAT-39). PCR products were purified by
filtration on a MultiScreenH-HV plate (Millipore) loaded with Bio-
GelH P-100 Gel solution (Bio-Rad Laboratories). Nucleotide
sequences were obtained from both ends using ABI PRISM
BigDye Terminator sequencing kits and the 3130 Xl Genetic
Analyzer (Applied Biosystems).
Microarray analysis
Microarray analysis was performed as previously reported [5].
GSEA [37] was used to evaluate the correlation of a specific gene
list with two different sample groups (genotypes). We used the
signal2noise ratio as a statistic to compare specific and gene set
permutations in order to evaluate statistical differences. Micro-
array data have been deposited in NCBI Gene Expression
Omnibus (GEO Series accession number: GSE10902).
mRNA analysis
Total RNA was isolated from wt and FHL2
2/2 MEFs with
RNeasy minikit (Qiagen). 1 mg of RNA was reverse-transcribed
using random primers and the Superscript Reverse Transcriptase
(Invitrogen). The primer sequences used in real-time PCR are
available upon request. The mean copy number of each gene from
a triplicate determination was normalized to the mean copy
number of 18S RNA.
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